LONDON — GSK’s once booming vaccines business faced new challenges in the third quarter as the company cut its vaccine sales forecast for this year.
In particular, quarterly sales of the company’s RSV vaccine, which has been a huge hit since its launch last year, fell more than 70% year-on-year, due in part to narrower recommendations for who should be vaccinated in the United States.
It was clear that sales for GSK’s vaccines division would decline this quarter. However, sales of both the RSV vaccine Aleksby and the company’s shingles vaccine Shingrix were lower than analysts expected.
STAT+ exclusive story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Subscribe to STAT+ for this article, plus daily coverage and analysis from the pharmaceutical industry.
Already have an account? Log in
Individual plan Group plan See all plans
To read the rest of this story, subscribe to STAT+.
Subscribe
Source link
